Search
for
Sort by
Research 181–210 of 522
- Treatment of frontal fibrosing alopecia: literature review 2020-2025
- Hair for the Long Haul: Alopecia Areata Cases and Considerations
- LB1034 Meta-analysis of scalp transcriptome defines alopecia areata subtypes and molecular response to four (4) treatments with jak inhibiting properties
- Current best evidence in pigmentary dermatology
- Wiederbehaarung bei einem Patienten mit Alopecia universalis und Psoriasis vulgaris unter Deucravacitinib‐Therapie
- Off-Label Treatment of Alopecia Areata—Retrospective Study
- Exploring the efficacy of baricitinib in treating alopecia areata after failed Janus kinase inhibitor therapy
- Janus kinase inhibitors for alopecia areata
- Selective Janus kinase 1 inhibition resolves inflammation and restores hair growth offering a viable treatment option for alopecia areata
- 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials
- Real-world evidence in alopecia areata treatment: A narrative review
- Microneedle-Mediated Transdermal Drug Delivery for the Treatment of Multiple Skin Diseases
- Single-Nucleus and Bulk RNA Sequencing Reveals the Involvement of Natural Killer and CD8+ T Cells in the Progression of Androgenetic Alopecia
- European expert consensus statement on the systemic treatment of alopecia areata
- JAK inhibitors in dermatology: The promise of a new drug class
- JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis
- Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata
- A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
- Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
- Hair Growth Effect of Emulsion Extracted Brevilin A, a JAK3 Inhibitor, from Centipeda minima
- Under Development JAK Inhibitors for Dermatologic Diseases
- 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
- UHPLC-Q-Orbitrap HRMS-based Metabolomics and In Silico Studies on 5-α-Reductase, JAK1, JAK2, and JAK3 of <i>Albizia saponaria</i> L.: Application to Alopecia
- Environmental Modulation of JAK3-Mediated Immune Dysregulation in Alopecia Areata
- CS12192 Reverses Alopecia Areata by Selectively Targeting JAK3/JAK1/TBK1.
- Discovery of a novel and highly selective JAK3 inhibitor as a potent hair growth promoter
- 695 Selectively targeting JAK1 or JAK3 pathway is sufficient to reverse alopecia areata
- 917 Frontal fibrosing alopecia scalp profiling links Th1/Th2 and JAK3 activation with fibrosis and loss of follicular stem cells
- In Silico Structure-Based Drug Design Approach To Evaluate Quercetin And Kaempferol As Dual Inhibitors Of Jak3 Kinase And 5-Alpha Reductase Type II with ADMET Profiling
- In Silico Structure-Based Drug Design Approach To Evaluate Quercetin And Kaempferol As Dual Inhibitors Of Jak3 Kinase And 5-Alpha Reductase Type II with ADMET Profiling